Physician profile
David D Meyer
NPI 1205879558
$154,798.70
in general payments reported to CMS, 2019-2025
20 companies · $810 in 2025
The $810 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $22K · 2021: $6,089 · 2022: $6,200 · 2023: $27K · 2024: $21K · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Travel and Lodging: $5,205 · Food and Beverage: $3,166 · Education: $68.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,670.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,636.50 |
| Travel and Lodging | $5,205.12 |
| Food and Beverage | $3,165.79 |
| Education | $68.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $83,451.02 | 2019-2025 | Evobrutinib, Mavenclad, Mavenclad |
| Alexion Pharmaceuticals, INC. | $48,756.17 | 2019-2024 | Ultomiris |
| Genzyme Corporation | $8,482.43 | 2019-2025 | |
| Allergan, INC. | $6,734.74 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $2,485.33 | 2020-2024 | Zeposia |
| Celgene Corporation | $1,419.61 | 2020-2024 | Zeposia |
| Sunovion Pharmaceuticals INC. | $1,050.00 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $836.69 | 2019 | |
| Biogen, INC. | $451.80 | 2019-2025 | Vumerity, Tysabri, Tecfidera |
| Novartis Pharmaceuticals Corporation | $441.85 | 2019-2024 | |
| Idorsia Pharmaceuticals US INC | $132.38 | 2022-2023 | Quviviq |
| Eisai INC. | $120.14 | 2024-2025 | |
| Amgen INC. | $110.65 | 2019 | |
| Abbvie INC. | $106.01 | 2025 | |
| Sanofi-Aventis U.S. LLC | $58.12 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $48.05 | 2023-2024 | |
| Argenx US, INC. | $35.48 | 2025 | Vyvgart Hytrulo |
| Merz Pharmaceuticals, LLC | $33.10 | 2023 | Xeomin |
| Horizon Therapeutics Plc | $28.52 | 2021 | |
| Lilly USA, LLC | $16.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.